- Home
- AMAL vs CDNA Comparison
AMAL vs CDNA Comparison
Compare AMAL & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMAL
- CDNA
- Stock Information
- Founded
- AMAL 1923
- CDNA 1998
- Country
- AMAL United States
- CDNA United States
- Employees
- AMAL N/A
- CDNA N/A
- Industry
- AMAL Commercial Banks
- CDNA Medical Specialities
- Sector
- AMAL Finance
- CDNA Health Care
- Exchange
- AMAL Nasdaq
- CDNA Nasdaq
- Market Cap
- AMAL 937.6M
- CDNA 1.0B
- IPO Year
- AMAL 2018
- CDNA 2014
- Fundamental
- Price
- AMAL $32.94
- CDNA $20.13
- Analyst Decision
- AMAL Buy
- CDNA Buy
- Analyst Count
- AMAL 2
- CDNA 6
- Target Price
- AMAL $38.50
- CDNA $30.33
- AVG Volume (30 Days)
- AMAL 197.0K
- CDNA 866.7K
- Earning Date
- AMAL 07-24-2025
- CDNA 07-30-2025
- Dividend Yield
- AMAL 1.68%
- CDNA N/A
- EPS Growth
- AMAL 9.81
- CDNA N/A
- EPS
- AMAL 3.36
- CDNA 1.07
- Revenue
- AMAL $303,970,000.00
- CDNA $346,421,000.00
- Revenue This Year
- AMAL $11.72
- CDNA $13.31
- Revenue Next Year
- AMAL $12.48
- CDNA $15.46
- P/E Ratio
- AMAL $9.92
- CDNA $18.99
- Revenue Growth
- AMAL 7.13
- CDNA 25.92
- 52 Week Low
- AMAL $25.03
- CDNA $14.09
- 52 Week High
- AMAL $38.19
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- AMAL 63.07
- CDNA 58.32
- Support Level
- AMAL $32.82
- CDNA $18.37
- Resistance Level
- AMAL $33.58
- CDNA $20.91
- Average True Range (ATR)
- AMAL 0.69
- CDNA 0.80
- MACD
- AMAL 0.15
- CDNA 0.06
- Stochastic Oscillator
- AMAL 81.70
- CDNA 69.88
About AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.